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Abstract
Introduction: In order to assess the significance of drug levels measured in intensive care medicine, clinical and
forensic toxicology, as well as for therapeutic drug monitoring, it is essential that a comprehensive collection of
data is readily available. Therefore, it makes sense to offer a carefully referenced compilation of therapeutic and
toxic plasma concentration ranges, as well as half-lives, of a large number of drugs and other xenobiotics for quick
and comprehensive information.
Methods: Data have been abstracted from original papers and text books, as well as from previous compilations,
and have been completed with data collected in our own forensic and clinical toxicology laboratory. The data
presented in the table and corresponding annotations have been developed over the past 20 years and longer. A
previous compilation has been completely revised and updated. In addition, more than 170 substances, especially
drugs that have been introduced to the market since 2003 as well as illegal drugs, which became known to cause
intoxications, were added. All data were carefully referenced and more than 200 new references were included.
Moreover, the annotations providing details were completely revised and more than 100 annotations were added.
Results: For nearly 1,000 drugs and other xenobiotics, therapeutic ("normal”) and, if data were available, toxic and
comatose-fatal blood-plasma concentrations and elimination half-lives were compiled in a table.
Conclusions: In case of intoxications, the concentration of the ingested substances and/or metabolites in blood
plasma better predicts the clinical severity of the case when compared to the assumed amount and time of
ingestion. Comparing and contrasting the clinical case against the data provided, including the half-life, may
support the decision for or against further intensive care. In addition, the data provided are useful for the
therapeutic monitoring of pharmacotherapies, to facilitate the diagnostic assessment and monitoring of acute and
chronic intoxications, and to support forensic and clinical expert opinions.
Introduction
In 2010, more than 3.95 million closed encounters regard-
ing unintentional and intentional exposures were logged
by the American Association of Poison Control Centers’
National Poison Data System and 2.38 million were related
to human exposures. Although the total encounters
showed a 7.7% decline from 2009, human exposures with
more serious outcomes increased 4.5%. Among the top
four substance classes most frequently involved in all
human exposures were two drug classes: analgesics
(11.5%), cosmetics/personal care products (7.7%), house-
hold cleaning substances (7.3%) and sedatives/hypnotics/
antipsychotics (6.0%) [1]. And a recent review describes
poisoning as the second leading cause of injury-related
morbidity and mortality in the United States, with more
than 2.4 million toxic exposures reported each year [2].
According to the UK’s National Poisons Information Ser-
vice Annual Report 2010/2011, poisoning is an extremely
common cause of hospital admissions in the National
Health Service, being numerically similar to admissions
for myocardial infarction [3].
In the case of intoxication or poisoning, the concentra-
tion of the ingested substance and/or metabolite better
predicts the clinical severity of the case and the potential
outcome when compared to the assumed amount and
time of ingestion. In addition, it is recommended that
plasma concentrations of drugs having a narrow thera-
peutic range or with a highly variable response (such as
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in psychiatry) have to be measured. This accounts for
anti-epileptics, cardiac glycosides, aminoglycosides, anti-
arrhythmics, theophylline, immunosuppressants, lithium,
antipsychotics and antidepressants, and antiretrovirals, as
well as for an increasing number of cytostatics and anti-
mycotics, among others. Apart from acute and chronic
intoxications, it is indicated to draw blood samples for
the following reasons: if doses are high and borderline, if
signs of overdosage occur although the dose is within
normal range (for example, genetic polymorphism), if
there is no efficacy although the dose is correct or if non-
adherence can be expected.
In general, plasma concentrations of drugs at steady
state are retrievable from the dosage and pharmacoki-
netic data. However, sufficient pharmacokinetic data are
often not available. Moreover, searching, retrieving,
reading, analysing and interpreting the relevant toxicolo-
gical and critical care literature in the case of acute
intoxications in daily intensive care practice is time-con-
suming and may delay or even mislead optimal clinical
decisions. Therefore, it makes sense to offer a carefully
referenced compilation of therapeutic and toxic plasma
concentration ranges, as well as half-lives, of a large
number of drugs and other xenobiotics for quick and
comprehensive information.
Materials and methods
The data presented in the table and the corresponding
annotations (Additional file 1) have been developed over
the past 20 years and longer. A previous compilation [4]
has been completely revised and updated. In addition,
more than 170 substances, especially drugs that have
been introduced to the market since then, as well as ille-
gal drugs, which became known to cause intoxications,
were added. All data were carefully referenced and more
than 200 new references were included. Moreover, the
annotations providing details were completely revised
and more than 100 annotations were added (see Addi-
tional file 1).
Reviews, text books, compilations of other authors
(mainly [5-31]) and, most importantly, original publica-
tions concerning individual drugs and case reports have
been used to set up and keep the database updated (see
Additional file 1). Experience gained over more than
25 years from working in the clinical and forensic toxi-
cological field contributed to the data presented (see
Additional file 1).
The substances were selected by clinical and toxicolo-
gical aspects, by frequency of prescribing or (mis-)use
and other matters in the area of internal intensive care
medicine as well as in clinical and forensic toxicology.
There is an increase in determining antibiotic, antire-
troviral and antimycotic concentrations using analytical
and chemical methods and there are special cases which
are closely monitored, although therapeutic concentra-
tions depend on the susceptibility of the microorganisms
and tissue concentrations are often more reliable.
The following clinical categories were used for group-
ing analytical data:
Therapeutic: blood-plasma concentrations (in general,
trough at steady state) observed following therapeuti-
cally effective doses; no or only minimal side effects
(drugs); “normal": concentrations associated with no or
only minimal toxic effects (other xenobiotics).
Toxic: blood-plasma concentrations which produce
toxicity/clinically relevant side effects/symptoms.
Comatose-fatal: blood-plasma (comatose) concentra-
tions and whole blood (fatal) concentrations reported to
have caused coma and death, respectively. Whether pub-
lished data for deaths refer to levels measured ante-mor-
tem or post-mortem (femoral or heart blood) is,
however, often unknown.
As no patient interventions were performed and this
compilation does not contain data on human experi-
mental research performed by the authors, ethical
review board approval is waived and informed consent
does not apply.
Results and discussion
For nearly 1,000 drugs and other xenobiotics, therapeu-
tic ("normal”) and, if data were available, toxic and
comatose-fatal plasma concentrations and elimination
half-lives were compiled in one table (see Additional file
1). The compilation primarily includes data for cen-
trally-active substances, such as hypnotics, sedatives,
anxiolytics, antipsychotics, lithium, antidepressants,
analgesics, anti-epileptics and stimulants as well as non-
steroidal anti-inflammatory drugs (NSAIDs), corticoster-
oids, antihistamines, antibiotics, antimycotics, antiretro-
virals, diuretics, ACE-inhibitors, sartanes, beta blockers,
calcium-channel blockers, cardiac glycosides, anti-
arrhythmics, anti-asthmatics, and local anesthetics,
among others.
In addition, and if data were available, other relevant
xenobiotics, such as controlled substances, illegal and
recreational drugs, heavy metals and pesticides among
others, were listed. To the best of our knowledge, this
compilation is the most current and comprehensive sin-
gle source of data necessary to support clinical decision
making in case of acute or chronic intoxications with
drugs and other xenobiotics.
When screening the data, it became obvious that for
many well known drugs there is insufficient pharmaco-
kinetic data available. However, for current substances,
little data are published about intoxications and their
plasma concentrations.
In general, therapeutic plasma concentration ranges or
concentrations found after therapeutic doses refer to
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trough levels (Cmin) at steady state. Inter-individual
deviation is, however, high. Therefore, any data listed
can only be taken as an orientation.
Often, it is not possible to find the threshold between
the therapeutic and toxic concentration for the specific
patient. This is, for instance, the case if tolerance devel-
ops (this is especially true for opioids) or drug/drug-
interactions or additional diseases are involved. In order
to keep the overall context clear, we preferred not to go
into further details.
Data about comatose or even fatal plasma concentra-
tions consciously orient on life threatening or lethal
intoxications which occurred at low plasma concentra-
tions so that actual and potential dangers in clinical cases
are not being underestimated. Many intoxicated patients
survived even with significantly higher concentrations.
It is also difficult to relate the concentrations to the
clinical picture because the interval between intake of
the drug and drawing a blood sample is generally
unknown. In any case, it is more reliable to have the
correct concentration measured rather than how much
drug/substance has probably been taken. Statements
about case histories are often not reliable. And often, it
is not known how much drug has been absorbed after
intake of charcoal, due to vomiting and/or irrigation of
the stomach.
For a variety of data representing lethal cases, it is not
known whether ante- or post-mortem, that is, (venous)
femoral or heart blood levels were measured. If this
information is unknown, we refrained from mentioning
this detail.
Elimination half-lives are statistically more reliable
than data gathered in case of intoxications. Yet even
with this data, substantial deviation can be expected. In
addition, most pharmacokinetic parameters are retrieved
from healthy subjects after application of relatively low
doses. The data indicated generally deal with the term-
inal elimination half-life, which most of the time is
higher than the half-life of the intended biological effect
(see annotations in the Additional file 1).
Conclusions
In case of intoxications, the concentration of the
ingested substance and/or metabolite in blood plasma
much better predicts the clinical severity of the case
when compared to the assumed amount and time of
ingestion. Comparing and contrasting the clinical case
against the data provided, including the half-life, may
support the decision for or against further intensive
care. In addition, the data provided are useful for the
therapeutic monitoring of pharmacotherapies, to facili-
tate the diagnostic assessment and monitoring of acute
and chronic intoxications as well as to support forensic
and clinical expert opinions.
Key messages
• Acute clinical intoxications are frequent.
• The concentration of the ingested substance better
predicts the clinical severity of the case when com-
pared to the assumed amount and time of ingestion.
• The most current and comprehensive single source
of data necessary to support the clinical decision
making in case of acute or chronic intoxications for
nearly 1,000 drugs and other xenobiotics is provided.
• Comparing and contrasting the clinical case against
the data provided, including the half-life, may sup-
port the decision for or against further intensive
care.
Additional material
Additional file 1: Therapeutic ("normal”), toxic, and comatose-fatal
blood-plasma concentrations (mg/L) in man. A table containing
therapeutic ("normal”), toxic, and comatose-fatal blood-plasma
concentrations (mg/L) of nearly 1,000 drugs and other xenobiotics in
humans, including annotations and references.
Abbreviations
appr.: approximately; AUC: area under the (plasma concentration-time) curve;
BAT: biological tolerance value (in the work area); Cmin: minimum (trough)
plasma concentration (usually at steady state); Cmax: maximum (peak) plasma
concentration; EM: extensive metaboliser; h: hours; mol wt: molecular
weight; NSAID: non-steroidal anti-inflammatory drug; PM: poor (slow)
metaboliser; Ref.; reference(s); SD: standard deviation; rec: recombinant; tmax:
time to peak plasma concentration (Cmax); t½: in general: terminal
elimination half-life (if not stated otherwise); TDM: therapeutic drug
monitoring.
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